GlassScriptPhysician profile
Cassandra Mueller
NPI 1407538093
$612.76
in general payments reported to CMS, 2019-2025
15 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $229 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $595 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $594.76 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $153.03 | 2024-2025 | Rotapro, Watchman Flx |
| Medtronic, INC. | $58.69 | 2024 | Corevalve Evolut R |
| Bridgebio Pharma, INC. | $50.92 | 2025 | Attruby |
| Pfizer INC. | $48.63 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $47.93 | 2025 | Camzyos |
| Novo Nordisk INC | $47.47 | 2024-2025 | Wegovy |
| Amgen INC. | $43.32 | 2024-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $37.01 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $28.27 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2025 | Jardiance |
| Solventum Corporation | $19.16 | 2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Actelion Pharmaceuticals US, INC. | $19.01 | 2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $16.23 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.55 | 2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $6.84 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.